A new Executive Informational Summary is now available on NEXGEL, Inc. (NASDAQ: NXGL), a company developing skin-friendly hydrogels for use in healthcare, cosmetics, and wellness. This 20-page report explores NEXGEL’s business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.
Snapshot
NEXGEL, Inc. (NXGL-NASDAQ) is a biotechnology company specializing in the development and manufacturing of advanced, high-water-content hydrogels for use in healthcare, medical device, cosmetic, and consumer wellness applications. Headquartered in Langhorne, Pennsylvania, the Company operates an FDA-registered and ISO-certified facility utilizing a proprietary electron-beam cross-linking process to produce ultra-gentle, skin-friendly hydrogel formulations. This technology enables long-lasting, breathable patches that deliver active ingredients through the skin without irritation or the use of chemical cross-linkers—making NEXGEL’s products ideal for wound care, scar treatment, drug delivery, and sensitive-skin cosmetics. The Company’s portfolio includes branded products such as SilverSeal®, MEDAGEL®, Turfguard®, and Kenkoderm®, as well as white-label manufacturing solutions. NEXGEL also offers contract development and packaging services through its CG Converting & Packaging subsidiary, allowing it to serve a wide range of clients across healthcare and consumer markets. Recent acquisitions, including the Silly George® beauty brand, reflect the Company’s strategic expansion into global personal care. With a scalable infrastructure, proprietary intellectual property (IP), and growing demand across multiple sectors, NEXGEL is well-positioned to lead innovation in topical delivery systems.
Key Points of NEXGEL, Inc.
- Innovative Hydrogel Technology Platform. NEXGEL’s proprietary hydrogels provide superior adhesion, breathability, and comfort for wound care, drug delivery, medical devices, and consumer health products.
- Diversified Business Model. The Company generates revenue from branded over-the-counter (OTC), private label, and Contract Development and Manufacturing Organization (CDMO) channels, providing flexibility, scale, and reduced market dependence.
- Integrated cGMP Manufacturing. NEXGEL’s FDA-compliant facility enables in-house research and development (R&D), production, and rapid innovation with quality control.
- Expanding IP Portfolio. The Company holds 17 active patents with additional filings covering formulations, processes, and applications.
- Strong Growth and Margins. NEXGEL’s Q1 2025 revenue rose 121% to $2.81 million, with gross margin improving to 42.4% on greater scale and efficiency.
- Solid Cash Position. As of March 31, 2025, NEXGEL had $1.19 million in cash to support operations and growth toward EBITDA breakeven.
*******************************************
Visit our Corporate Profile and Investment Highlights pages
for the latest research on NEXGEL, Inc.
*******************************************